Intensive Intracranial Pressure and Temperature Monitoring May Improve the Outcome of a Young Patient with Severe Cryptogenic New-onset Refractory Status Epilepticus: A Case Report
View abstract on PubMed
Summary
This summary is machine-generated.New-onset refractory status epilepticus (NORSE) can be challenging. Intensive intracranial pressure management and thermoregulation significantly improved a young patient
Area Of Science
- Neurology
- Neurosurgery
Background
- New-onset refractory status epilepticus (NORSE) is characterized by sudden, severe, and difficult-to-control seizures in young individuals without prior epilepsy history.
- Neurosurgical interventions for NORSE are typically palliative or diagnostic.
- This case highlights a potential therapeutic approach for NORSE.
Purpose Of The Study
- To report a case of significant patient improvement following intensive intracranial pressure management for new-onset refractory status epilepticus.
- To explore the role of neurosurgical interventions beyond palliation in NORSE.
Main Methods
- A 20-year-old male with NORSE underwent percutaneous thermoregulation to 37°C to suppress electrographic seizures.
- Intracranial pressure (ICP) monitoring and ventriculostomy were performed to manage elevated ICP.
- Treatment involved a combination of medical management, thermoregulation, and ICP control.
Main Results
- Thermoregulation partially suppressed electrographic seizures.
- ICP management was initiated due to uncontrolled seizures.
- The patient showed significant improvement in wakefulness (Glasgow Coma Scale from 3 to 8) and functional status (modified Rankin Score of 1) after 13 days of intensive management.
- Seizure episodes ceased by day 22.
Conclusions
- Intensive intracranial pressure management, alongside other interventions like thermoregulation, can lead to significant recovery in patients with new-onset refractory status epilepticus.
- Neurosurgical interventions should be strongly considered in the management of NORSE, given its grave prognosis.
- This case suggests that aggressive ICP management may offer a more substantial benefit than previously recognized in NORSE.

